INTENSITY THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
INTS$3.15+5.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance sheets as of December 31, and
BALANCE SHEETS
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $8,556 | $1,312 |
| Marketable debt securities | 6,220 | - |
| Prepaid expenses | 682 | 63 |
| Other current assets | 6 | 76 |
| Total current assets | 15,464 | 1,451 |
| Right-of-use asset, net | 147 | 139 |
| Other assets | 1,684 | 167 |
| Total assets | $17,295 | $1,757 |
| LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||
| Current liabilities: | ||
| Accounts payable | $3,048 | $603 |
| Accrued expenses | 891 | 1,724 |
| Lease liability, current portion | 20 | 143 |
| Convertible note and accrued interest | - | 4,349 |
| Total current liabilities | 3,959 | 6,819 |
| Other long-term liabilities | 36 | 36 |
| Lease liability, net of long-term portion | 138 | - |
| Total liabilities | $4,133 | $6,855 |
| Series A redeemable convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 5,000,000 as of December 31, 2023 and 2022, respectively. | - | 10,000 |
| Commitments and contingencies | ||
| STOCKHOLDERS’ EQUITY (DEFICIENCY) | ||
| Preferred stock, par value $.0001. Authorized shares of 15,000,000 and 20,000,000 as of December 31, 2023 and 2022, respectively. | - | - |
| Series B convertible preferred stock, par value $.0001. Designated, issued, and outstanding shares of none and 1,449,113 as of December 31, 2023 and 2022, respectively. | - | - |
| Series C convertible preferred stock, par value $.0001. Designated, issued, and outstanding shares of none and 1,800,606 as of December 31, 2023 and 2022, respectively. | - | - |
| Common stock, par value $.0001. Authorized shares of 135,000,000 and 50,000,000 as of December 31, 2023 and 2022, respectively. Issued and outstanding shares of 13,709,377 and 3,410,103 as of December 31, 2023 and 2022, respectively. | 1 | - |
| Additional paid-in capital | 63,676 | 23,555 |
| Accumulated deficit | (50,515) | (38,653) |
| Total stockholders’ equity (deficiency) | $13,162 | $(15,098) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficiency) | $17,295 | $1,757 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.